Sumitomo Pharma is cutting 62 jobs in New York City, according to a WARN notice filed with the state, after saying in April that it planned to combine its seven wholly-owned US subsidiaries.
Sumitovant Biopharma said in the notice that the plant layoffs are a “result of the integration of Sumitovant and a number of its affiliates into one new company, Sumitomo Pharma America.” Another three employees are expected to be let go on Oct. 5.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters